GLP-1 agonists, including tirzepatide, offer significant therapeutic benefits for T2DM and obesity but carry risks of rare adverse effects like acute pancreatitis. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.